Catalyst Pharm Inc (CPRX) Stock Price, Quote & News

Company Profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 420 3200

Website: catalystpharma.com

Address:

355 Alhambra Circle, Suite 801, Coral Gables, United States

BadStockAdvice Oct. 4 at 2:53 AM

$CPRX @BigGainTom stuck bagholding this garbage

0 · Reply

flybyme Oct. 3 at 6:10 AM

$CPRX Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy https://www.santhera.com/assets/files/press-releases/Canada-approval_Final.pdf

0 · Reply

111ggg Oct. 2 at 1:37 PM

$CPRX going right back to where it belongs. 19-20. Like I posted yesterday, buyback releases mean nothing. Only large day traders make money on those type of news releases. The little retail guy buys high as the rraders are sellin high. Now all the little guys are pissed.

1 · Reply

ShortsHater Oct. 2 at 12:11 AM

$BCRX should follow $CPRX example of share repurchase

0 · Reply

jwsh123 Oct. 1 at 7:39 PM

$CPRX Does anyone has any speculation on how the 200M stock buyback has to do with the patent fight?

0 · Reply

druvaciam Oct. 1 at 5:36 PM

$CPRX Short attack?

0 · Reply

druvaciam Oct. 1 at 5:36 PM

$CPRX What is going on? I was thinking it is moving to the moon..

0 · Reply

111ggg Oct. 1 at 5:34 PM

$CPRX Back to 20 or less. How happy are all the suckers who bought near 22?

0 · Reply

111ggg Oct. 1 at 5:29 PM

$CPRX What a joke. They pulled this crap a few years ago and only bought back a fraction of announced share buyback. Again, this is simply a bogus number pulled out of a hat to appease holders. It is simply an authorization to buy back shares.

0 · Reply

111ggg Oct. 1 at 5:16 PM

$CPRX Not even a one day event. Half day event.

0 · Reply

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

Aug 28, 2025, 8:03 AM EDT - 5 weeks ago

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:12 PM EDT - 5 weeks ago

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Aug 25, 2025, 8:03 AM EDT - 5 weeks ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Aug 7, 2025, 2:21 PM EDT - 2 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:13 PM EDT - 2 months ago

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Aug 6, 2025, 8:03 AM EDT - 2 months ago

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

Aug 4, 2025, 8:03 AM EDT - 2 months ago

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

Jul 22, 2025, 8:03 AM EDT - 2 months ago

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:08 AM EDT - 4 months ago

Strong Inflows Make Catalyst Stock an Outlier

Jun 11, 2025, 7:00 AM EDT - 4 months ago

20 stocks you should avoid — no matter how well the market does

CORT CRK CRNC DDD LUMN LYV MGPI

Jun 2, 2025, 8:03 AM EDT - 4 months ago

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

May 31, 2025, 5:18 AM EDT - 4 months ago

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma

May 8, 2025, 12:02 PM EDT - 5 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:14 PM EDT - 5 months ago

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 8:03 AM EDT - 5 months ago

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

Apr 22, 2025, 8:03 AM EDT - 5 months ago

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 8, 2025, 8:06 AM EDT - 6 months ago

Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

Mar 26, 2025, 8:12 AM EDT - 6 months ago

Strong Revenue, Drug Performance Lift Catalyst Shares

Mar 11, 2025, 4:05 AM EDT - 7 months ago

Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts

Mar 4, 2025, 8:03 AM EST - 7 months ago

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

Mar 3, 2025, 2:39 PM EST - 7 months ago

Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges

Feb 27, 2025, 12:29 PM EST - 7 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:13 PM EST - 7 months ago

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 8:03 AM EST - 8 months ago

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Feb 7, 2025, 3:56 PM EST - 8 months ago

Catalyst Remains a Big Money Favorite

Jan 23, 2025, 8:03 AM EST - 9 months ago

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

Jan 21, 2025, 8:19 AM EST - 9 months ago

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

Jan 13, 2025, 8:30 AM EST - 9 months ago

Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE

Jan 8, 2025, 12:30 PM EST - 9 months ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Dec 16, 2024, 8:03 AM EST - 10 months ago

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 8:03 AM EST - 11 months ago

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Nov 13, 2024, 8:03 AM EST - 11 months ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

Nov 7, 2024, 10:34 AM EST - 11 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:12 PM EST - 11 months ago

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 8, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

Oct 1, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024

Sep 24, 2024, 6:00 AM EDT - 1 year ago

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan

Sep 12, 2024, 1:00 AM EDT - 1 year ago

Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In August

CAH VRNA

Aug 8, 2024, 1:30 PM EDT - 1 year ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:11 PM EDT - 1 year ago

Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

VRDN VRNA

Jul 24, 2024, 8:05 AM EDT - 1 year ago

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

Jul 22, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 17, 2024, 11:57 AM EDT - 1 year ago

These small-cap stocks score highest when screened for quality

CALX CARG CORT GOGO MC MYRG PLMR

May 30, 2024, 1:41 PM EDT - 1 year ago

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

May 28, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

May 9, 2024, 10:52 AM EDT - 1 year ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript

BadStockAdvice Oct. 4 at 2:53 AM

$CPRX @BigGainTom stuck bagholding this garbage

0 · Reply

flybyme Oct. 3 at 6:10 AM

$CPRX Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy https://www.santhera.com/assets/files/press-releases/Canada-approval_Final.pdf

0 · Reply

111ggg Oct. 2 at 1:37 PM

1 · Reply

ShortsHater Oct. 2 at 12:11 AM

$BCRX should follow $CPRX example of share repurchase

0 · Reply

jwsh123 Oct. 1 at 7:39 PM

$CPRX Does anyone has any speculation on how the 200M stock buyback has to do with the patent fight?

0 · Reply

druvaciam Oct. 1 at 5:36 PM

$CPRX Short attack?

0 · Reply

druvaciam Oct. 1 at 5:36 PM

$CPRX What is going on? I was thinking it is moving to the moon..

0 · Reply

111ggg Oct. 1 at 5:34 PM

$CPRX Back to 20 or less. How happy are all the suckers who bought near 22?

0 · Reply

111ggg Oct. 1 at 5:29 PM

0 · Reply

111ggg Oct. 1 at 5:16 PM

$CPRX Not even a one day event. Half day event.

0 · Reply

BigGainTom Oct. 1 at 4:24 PM

$CPRX Nice spike today. I decided to sell my 4000 shares after holding for months. Good luck for everyone. Will buy back closer to $20.

0 · Reply

AnchorMB Oct. 1 at 3:01 PM

$CPRX CPRX is great! Check out OCGN! It's flying too! These are my 2 stocks!

0 · Reply

JazzyJ03 Oct. 1 at 2:31 PM

$CPRX

0 · Reply

StillWaiting101 Oct. 1 at 2:05 PM

$CPRX its beautiful, we needed this, volume had been picking up on some of those down days, this tells big money to relax, they made a move and showed they are willing to invest in their own company.

2 · Reply

leprechaun612 Oct. 1 at 2:00 PM

$CPRX Catalyst Has approximately 122 million shares outstanding There are ballpark figure of $21 Per share that 200 million would be nine million shares

0 · Reply

111ggg Oct. 1 at 1:38 PM

$CPRX this is one day event before short attack. They will never use up to 200m of their precious cash.

1 · Reply

StillWaiting101 Oct. 1 at 12:40 PM

$CPRX there is some action from management, break $20.40 and we are rolling again

2 · Reply

JackCampbell Oct. 1 at 12:36 PM

$CPRX up to 200m usd repurchase of shrs is really a huge amount! wow

1 · Reply

toradio Oct. 1 at 12:23 PM

$CPRX stock buy back plan announced

0 · Reply

highnihilism Sep. 30 at 12:12 PM

$AESI Atlas Energy Solutions: 94 trades, $16K vs $119K avg (0.14x). $15K calls / $1K puts. $CPRX Catalyst Pharmaceuticals: 54 trades, $20K vs $57K avg (0.36x). $15K calls / $5K puts. $SID Companhia Siderurgica Nacional: 19 trades, $15K vs $10K avg (1.51x). $15K calls / $0.1K puts. $HMC Honda Motor Company: 106 trades, $31K vs $380K avg (0.08x). $15K calls / $16K puts.

0 · Reply

StillWaiting101 Sep. 29 at 6:38 PM

$CPRX XBI is up 1.3% today, still think we are being punished and without some kind of news, the powers that be are looking for that capitulation, hopefully I am wrong, but this action doesn't inspire me to believe they are done trying to push management to action

0 · Reply

Hello166388 Sep. 29 at 6:07 PM

$CPRX

0 · Reply

Market Cap	2.55B
Revenue (ttm)	491.73M
Net Income (ttm)	163.89M
EPS (ttm)	N/A
PE Ratio	8.57
Forward PE	9.55
Profit Margin	33.33%
Debt to Equity Ratio	0.00

Volume	1,068,400
Avg Vol	1,594,542
Day's Range	N/A - N/A
Shares Out	122.39M
Stochastic %K	60%
Beta	0.79
Analysts	Strong Sell
Price Target	$34.00